Ovarian Cancer Drug Approval Tops SPT Week in Review


5. Opioid Duration, Not Dosage May Be Key to Reducing Misuse in Surgical Patients

The researchers found that total duration of opioid use was the strongest predictor of misuse, with each refill and additional week of opioid use associated with an increased rate of misuse. Read more.

4. Nearly Half of Patients in Trial Respond to Checkpoint Inhibitor Treatment for Common Skin Cancer

Cemiplimab induced a response in approximately half of patients with advanced cutaneous squamous-cell carcinoma. Read more.

 


3. Multiple Sclerosis Drug Reduces Disease Activity, Disability Progression in Trials

Ocrelizumab showed a sustained reduction in underlying disease activity and improved cognitive function in patients with relapsing multiple sclerosis. Read more.

 


2. FDA OKs Keytruda for Relapsed/Refractory PMBCL, Advanced Cervical Cancer

Pembrolizumab (Keytruda, Merck) gained FDA approval for 2 new oncology indications. Read more.

 


1. FDA Approves Bevacizumab with Chemotherapy for Ovarian Cancer

Officials with the FDA have approved bevacizumab (Avastin, Genentech) in combination with carboplatin and paclitaxel for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Read more.



Source link

Leave a Reply

Your email address will not be published.